Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of...

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting...

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to...

Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual...

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the...

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of...

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based,...

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma...

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of...

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical...

Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients...

Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand...

Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC;...

Please visit answersincme.com/ZUU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology and oncology discusses the clinical implications of approved and emerging anti–lymphocyte activation gene-3 (LAG-3)/programmed cell death protein 1 (PD-1) combinations in advanced melanoma. Upon completion of this activity, participants should be better able to: Outline the current unmet treatment needs for...

Please visit answersincme.com/DNA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and dermatology discuss therapeutic options in the first-line treatment of advanced melanoma and the role of the multidisciplinary team in maximizing treatment outcomes. Upon completion of this activity, participants should be better able to: Identify the unmet clinical needs for patients with advanced melanoma;...

Please visit answersincme.com/BRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging strategies to optimize the multidisciplinary care of advanced basal cell carcinoma (BCC) with immunotherapy.Upon completion of this activity, participants should be better able to: Identify patients with BCC for whom a second-line immunotherapy regimen would be appropriate; Review the...

Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque...

Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for...

Please visit answersincme.com/GDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the clinical impact of approved and emerging combination treatments for advanced melanoma. Upon completion of this activity, participants should be better able to: Identify the unmet treatment needs for patients with advanced melanoma within the current therapeutic landscape; Recognize the mechanism of action of...

Please visit answersincme.com/WZE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies for optimizing immunotherapy in advanced basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Identify patients with advanced BCC who may benefit from immunotherapy; Review the clinical impact of available and emerging immunotherapies for the...

Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD;...

Please visit answersincme.com/GZT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the latest data in systemic treatments for children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the rationale for treatment intensification with novel systemic agents when managing children with moderate-to-severe atopic...

Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive...

Please visit answersincme.com/MTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in eosinophilic gastrointestinal disease discusses the diagnosis and underlying pathophysiology targeted by potential treatments for eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Describe the burden associated with delayed detection and inadequate treatment of EoE;...